CETN2 and glioblastoma: For CETN2, MKI67, ARL13B, and SETDB1, patients with high expression experienced a worse OS, while high expression of CALN1, ELAVL3, ADCY3, SYN2, ARL13B, SLC12A5, and SOD1 were associated with better overall survival among patients with GBM.